Optimising viral vector manufacturing with CDMO expertise and innovation | Fierce Biotech

This article from Fierce Biotech discusses GSK's acquisition of near-approval therapies for lung cancer treatment. The content focuses on competitive dynamics in oncology rather than detailing a specific CDMO's capabilities, infrastructure, or service offerings.